Core Viewpoint - Phibro Animal Health (PAHC) has experienced a significant share price increase of 87.5% over the past year, outperforming the industry and S&P 500, driven by strong demand across its diversified portfolio, particularly in the Vaccine business and international markets [1][3]. Company Overview - Phibro is headquartered in New Jersey and offers a wide range of products for food animals, including poultry, swine, beef, dairy cattle, and aquaculture, while also producing ingredients for various industries [2]. - The company is focusing on expanding its product offerings in the companion animal sector [2]. Key Factors Behind PAHC's Surge - The surge in share price is attributed to robust demand for animal health products, with the Animal Health segment reporting a 32.5% year-over-year sales growth, driven by a 47% increase in MFA and other product sales [3]. - The acquisition of Zoetis' medicated feed additive product portfolio has expanded Phibro's offerings to over 37 product lines across 80 countries [3]. - The Vaccine business achieved a 12% growth, supported by new poultry products in Latin America and increased demand globally [4]. - Phibro's international sales accounted for approximately 40.4% of total revenues in the fiscal second quarter, highlighting its global growth potential [5]. Financial Estimates - The Zacks Consensus Estimate projects a 62.2% increase in earnings per share (EPS) for fiscal 2025, reaching $1.93, and an 8.7% increase for fiscal 2026, reaching $2.10 [9]. - Revenues for fiscal 2025 are expected to grow by 25.9% to $1.28 billion, with fiscal 2026 projected to reach $1.38 billion, implying a 7.7% increase [9].

As filed with the U.S. Securities and Exchange Commission on March 7, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ DUNE ACQUISITION CORPORATION II (Exact name of registrant as specified in its charter) ____________________ Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classificat ...

Company Overview - Mobile-health Network Solutions (MNDR) is a pioneering MedTech company focused on enhancing human connection through technology [1] - The company is ranked 41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies and is the first telehealth provider from the Asia-Pacific region to be listed in the US [4] - MNDR offers a range of telehealth solutions including teleconsultation services, prescription fulfillment, and personalized services such as weight management programs and gender-specific care [4] Upcoming Events - MNDR will present at the Centurion One Capital 8th Annual Growth Conference from March 3rd to March 6th, 2025, at the Four Seasons Hotel in Toronto [1][3] - Co-founders and co-CEOs, Dr. Tung Yeng Siaw and Dr. Rachel Teoh, are scheduled to present on March 6th, 2025, focusing on the company's latest AI technology innovations [2] - The presentation will include the newly deployed AI Agent platform aimed at improving healthcare providers' workflow efficiency [2] Industry Context - The telehealth solutions industry is experiencing growth, with MNDR positioned to capitalize on this trend through its innovative technology and services [4] - Centurion One Capital, the investment banking firm hosting the conference, is dedicated to supporting the growth of companies in North America, indicating a favorable environment for investment in the sector [5][6]